{"title":"日本类风湿关节炎患者体内羟氯喹浓度与其疗效和安全性之间的关系","authors":"Hiroshi Takei, Masayuki Hashiguchi, Satoshi Takanashi, Hironari Hanaoka, Jun Kikuchi, Keiko Yoshimoto, Tsuyoshi Shiga, Mikiko Shimizu, Tsutomu Takeuchi, Yuko Kaneko","doi":"10.1093/mr/roaf033","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between serum concentrations of hydroxychloroquine (HCQ) and its derivatives and clinical efficacy in Japanese patients with rheumatoid arthritis.</p><p><strong>Methods: </strong>Patients with active RA despite conventional synthetic disease-modifying antirheumatic drugs were recruited, and HCQ was administered for 24 weeks in addition to the prior treatment. Serum concentrations of HCQ, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ) and bisdesethylchloroquine (BCQ) were measured at weeks 0, 4, 8, 12, 24, and 32. Association between each serum concentration and achievement of American College of Rheumatology (ACR) 20/50/70 was analyzed.</p><p><strong>Results: </strong>Forty-nine patients whose sera were available were included in the analysis. The serum concentrations of HCQ, DHCQ, DCQ and BCQ reached plateau at week 4 and remained at the stable levels during the 24 weeks. The concentrations of HCQ, DHCQ, DCQ and BCQ at week 24 was higher in patients who achieved ACR20 than in those who did not. Furthermore, higher serum concentrations of DHCQ and BCQ were also associated with the achievement of ACR50 and ACR70, while those of HCQ and DCQ were not.</p><p><strong>Conclusion: </strong>Serum concentrations of HCQ and its derivatives are associated with clinical effectiveness of HCQ in Japanese patients with rheumatoid arthritis.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between hydroxychloroquine concentrations and its efficacy and safety in Japanese patients with rheumatoid arthritis.\",\"authors\":\"Hiroshi Takei, Masayuki Hashiguchi, Satoshi Takanashi, Hironari Hanaoka, Jun Kikuchi, Keiko Yoshimoto, Tsuyoshi Shiga, Mikiko Shimizu, Tsutomu Takeuchi, Yuko Kaneko\",\"doi\":\"10.1093/mr/roaf033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the association between serum concentrations of hydroxychloroquine (HCQ) and its derivatives and clinical efficacy in Japanese patients with rheumatoid arthritis.</p><p><strong>Methods: </strong>Patients with active RA despite conventional synthetic disease-modifying antirheumatic drugs were recruited, and HCQ was administered for 24 weeks in addition to the prior treatment. Serum concentrations of HCQ, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ) and bisdesethylchloroquine (BCQ) were measured at weeks 0, 4, 8, 12, 24, and 32. Association between each serum concentration and achievement of American College of Rheumatology (ACR) 20/50/70 was analyzed.</p><p><strong>Results: </strong>Forty-nine patients whose sera were available were included in the analysis. The serum concentrations of HCQ, DHCQ, DCQ and BCQ reached plateau at week 4 and remained at the stable levels during the 24 weeks. The concentrations of HCQ, DHCQ, DCQ and BCQ at week 24 was higher in patients who achieved ACR20 than in those who did not. Furthermore, higher serum concentrations of DHCQ and BCQ were also associated with the achievement of ACR50 and ACR70, while those of HCQ and DCQ were not.</p><p><strong>Conclusion: </strong>Serum concentrations of HCQ and its derivatives are associated with clinical effectiveness of HCQ in Japanese patients with rheumatoid arthritis.</p>\",\"PeriodicalId\":18705,\"journal\":{\"name\":\"Modern Rheumatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mr/roaf033\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roaf033","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：探讨日本类风湿关节炎患者血清羟氯喹（HCQ）及其衍生物浓度与临床疗效的关系。方法：招募有常规合成疾病改善抗风湿药物的活动性RA患者，在先前治疗的基础上给予HCQ治疗24周。测定血清HCQ、去乙基羟氯喹（DHCQ）、去乙基氯喹（DCQ）和双去乙基氯喹（BCQ）在第0、4、8、12、24和32周的浓度。分析各血清浓度与美国风湿病学会（American College of Rheumatology， ACR）评分20/50/70之间的关系。结果：49例可获得血清的患者纳入分析。血清HCQ、DHCQ、DCQ和BCQ浓度在第4周达到平台，并在24周内保持稳定。在第24周，达到ACR20的患者的HCQ、DHCQ、DCQ和BCQ浓度高于未达到ACR20的患者。此外，较高的DHCQ和BCQ血清浓度也与ACR50和ACR70的实现相关，而HCQ和DCQ血清浓度与ACR50和ACR70的实现无关。结论：日本类风湿关节炎患者血清中HCQ及其衍生物浓度与HCQ的临床疗效相关。
Association between hydroxychloroquine concentrations and its efficacy and safety in Japanese patients with rheumatoid arthritis.
Objective: To evaluate the association between serum concentrations of hydroxychloroquine (HCQ) and its derivatives and clinical efficacy in Japanese patients with rheumatoid arthritis.
Methods: Patients with active RA despite conventional synthetic disease-modifying antirheumatic drugs were recruited, and HCQ was administered for 24 weeks in addition to the prior treatment. Serum concentrations of HCQ, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ) and bisdesethylchloroquine (BCQ) were measured at weeks 0, 4, 8, 12, 24, and 32. Association between each serum concentration and achievement of American College of Rheumatology (ACR) 20/50/70 was analyzed.
Results: Forty-nine patients whose sera were available were included in the analysis. The serum concentrations of HCQ, DHCQ, DCQ and BCQ reached plateau at week 4 and remained at the stable levels during the 24 weeks. The concentrations of HCQ, DHCQ, DCQ and BCQ at week 24 was higher in patients who achieved ACR20 than in those who did not. Furthermore, higher serum concentrations of DHCQ and BCQ were also associated with the achievement of ACR50 and ACR70, while those of HCQ and DCQ were not.
Conclusion: Serum concentrations of HCQ and its derivatives are associated with clinical effectiveness of HCQ in Japanese patients with rheumatoid arthritis.
期刊介绍：
Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery.
Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered.
Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
